308 related articles for article (PubMed ID: 21653308)
1. Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era.
Bedimo RJ; Westfall AO; Drechsler H; Vidiella G; Tebas P
Clin Infect Dis; 2011 Jul; 53(1):84-91. PubMed ID: 21653308
[TBL] [Abstract][Full Text] [Related]
2. Renal toxicity of long-term therapy with tenofovir in HIV-infected patients.
Monteagudo-Chu MO; Chang MH; Fung HB; Bräu N
J Pharm Pract; 2012 Oct; 25(5):552-9. PubMed ID: 22551561
[TBL] [Abstract][Full Text] [Related]
3. Abacavir and risk of myocardial infarction in HIV-infected patients on highly active antiretroviral therapy: a population-based nationwide cohort study.
Obel N; Farkas DK; Kronborg G; Larsen CS; Pedersen G; Riis A; Pedersen C; Gerstoft J; Sørensen HT
HIV Med; 2010 Feb; 11(2):130-6. PubMed ID: 19682101
[TBL] [Abstract][Full Text] [Related]
4. Renal function and incidence of chronic kidney disease in HIV patients: a Danish cohort study.
Rasch MG; Engsig FN; Feldt-Rasmussen B; Kirk O; Kronborg G; Pedersen C; Gerstoft J; Obel N
Scand J Infect Dis; 2012 Sep; 44(9):689-96. PubMed ID: 22680981
[TBL] [Abstract][Full Text] [Related]
5. Acute myocardial infarction associated with abacavir and tenofovir based antiretroviral drug combinations in the United States.
Dorjee K; Desai M; Choden T; Baxi SM; Hubbard AE; Reingold AL
AIDS Res Ther; 2021 Sep; 18(1):57. PubMed ID: 34488812
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy.
Pavie J; Porcher R; Torti C; Medrano J; Castagna A; Valin N; Rusconi S; Ammassari A; Ghosn J; Delaugerre C; Molina JM;
J Antimicrob Chemother; 2011 Oct; 66(10):2372-8. PubMed ID: 21821627
[TBL] [Abstract][Full Text] [Related]
7. [Current data on antiretroviral therapy. CROI 2009: tenofovir DR convinces by high effectiveness and tolerance].
Walter M
MMW Fortschr Med; 2009 Apr; 151(18):76-9. PubMed ID: 19769084
[No Abstract] [Full Text] [Related]
8. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy.
Moyle GJ; Sabin CA; Cartledge J; Johnson M; Wilkins E; Churchill D; Hay P; Fakoya A; Murphy M; Scullard G; Leen C; Reilly G;
AIDS; 2006 Oct; 20(16):2043-50. PubMed ID: 17053350
[TBL] [Abstract][Full Text] [Related]
9. Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4.
Lang S; Mary-Krause M; Cotte L; Gilquin J; Partisani M; Simon A; Boccara F; Costagliola D;
Arch Intern Med; 2010 Jul; 170(14):1228-38. PubMed ID: 20660842
[TBL] [Abstract][Full Text] [Related]
10. Renal function declines more in tenofovir- than abacavir-based antiretroviral therapy in low-body weight treatment-naïve patients with HIV infection.
Nishijima T; Gatanaga H; Komatsu H; Tsukada K; Shimbo T; Aoki T; Watanabe K; Kinai E; Honda H; Tanuma J; Yazaki H; Honda M; Teruya K; Kikuchi Y; Oka S
PLoS One; 2012; 7(1):e29977. PubMed ID: 22242194
[TBL] [Abstract][Full Text] [Related]
11. Effect of abacavir on acute changes in biomarkers associated with cardiovascular dysfunction.
Patel P; Bush T; Overton T; Baker J; Hammer J; Kojic E; Conley L; Henry K; Brooks JT;
Antivir Ther; 2012; 17(4):755-61. PubMed ID: 22301072
[TBL] [Abstract][Full Text] [Related]
12. Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial.
Martin A; Bloch M; Amin J; Baker D; Cooper DA; Emery S; Carr A
Clin Infect Dis; 2009 Nov; 49(10):1591-601. PubMed ID: 19842973
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular risks associated with abacavir and tenofovir exposure in HIV-infected persons.
Choi AI; Vittinghoff E; Deeks SG; Weekley CC; Li Y; Shlipak MG
AIDS; 2011 Jun; 25(10):1289-98. PubMed ID: 21516027
[TBL] [Abstract][Full Text] [Related]
14. Improvement in bone mineral density after switching from tenofovir to abacavir in HIV-1-infected patients with low bone mineral density: two-centre randomized pilot study (OsteoTDF study).
Negredo E; Domingo P; Pérez-Álvarez N; Gutiérrez M; Mateo G; Puig J; Escrig R; Echeverría P; Bonjoch A; Clotet B
J Antimicrob Chemother; 2014 Dec; 69(12):3368-71. PubMed ID: 25125679
[TBL] [Abstract][Full Text] [Related]
15. Low-density lipoprotein size and lipoprotein-associated phospholipase A2 in HIV-infected patients switching to abacavir or tenofovir.
Saumoy M; Ordoñez-Llanos J; Martínez E; Barragán P; Ribera E; Bonet R; Knobel H; Negredo E; Loncá M; Curran A; Gatell JM; Podzamczer D;
Antivir Ther; 2011; 16(4):459-68. PubMed ID: 21685533
[TBL] [Abstract][Full Text] [Related]
16. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment.
Smith KY; Patel P; Fine D; Bellos N; Sloan L; Lackey P; Kumar PN; Sutherland-Phillips DH; Vavro C; Yau L; Wannamaker P; Shaefer MS;
AIDS; 2009 Jul; 23(12):1547-56. PubMed ID: 19542866
[TBL] [Abstract][Full Text] [Related]
17. Early markers of tubular dysfunction in antiretroviral-experienced HIV-infected patients treated with tenofovir versus abacavir.
Maggi P; Montinaro V; Bellacosa C; Pietanza S; Volpe A; Graziano G; Strippoli GF; Angarano G
AIDS Patient Care STDS; 2012 Jan; 26(1):5-11. PubMed ID: 22136504
[TBL] [Abstract][Full Text] [Related]
18. Early changes in inflammatory and pro-thrombotic biomarkers in patients initiating antiretroviral therapy with abacavir or tenofovir.
Padilla S; Masiá M; García N; Jarrin I; Tormo C; Gutiérrez F
BMC Infect Dis; 2011 Feb; 11():40. PubMed ID: 21294867
[TBL] [Abstract][Full Text] [Related]
19. Abacavir, didanosine and tenofovir do not induce inflammatory, apoptotic or oxidative stress genes in coronary endothelial cells.
Kim C; Gupta SK; Green L; Taylor BM; Deuter-Reinhard M; Desta Z; Clauss M
Antivir Ther; 2011; 16(8):1335-9. PubMed ID: 22155915
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of telomerase activity by human immunodeficiency virus (HIV) nucleos(t)ide reverse transcriptase inhibitors: a potential factor contributing to HIV-associated accelerated aging.
Leeansyah E; Cameron PU; Solomon A; Tennakoon S; Velayudham P; Gouillou M; Spelman T; Hearps A; Fairley C; Smit de V; Pierce AB; Armishaw J; Crowe SM; Cooper DA; Koelsch KK; Liu JP; Chuah J; Lewin SR
J Infect Dis; 2013 Apr; 207(7):1157-65. PubMed ID: 23303810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
